References
- Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300
- World Health Organization. Hepatitis C Fact Sheet Number 164. July 2015. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ Accessed 1 February 2017
- Feld JJ. Genotype 3 HCV: still difficult to treat? Clinical Thoughts in HCV Management. 10 February 2015. Available at: http://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/All%20Oral%20Therapy/ Clinical%20Thoughts/CT2.aspx [Last accessed 10 April 2015]
- Germer JJ, Mandrekar JN, Bendel JL, et al. Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol 2011;49:3040-3
- Manos MM, Shvachko VA, Murphy RC, et al. Distribution of hepatitis C virus genotypes in a diverse U.S. integrated health care population. J Med Virol 2012;84:1744-50
- Young AM, Crosby RA, Oser CB, et al. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012;84:1376-87
- Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis. J Viral Hepat 2011;18:745-59
- Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011;18:e516-22
- Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. veterans with HCV. Hepatology 2014;60:98-105
- Mccombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014;174:204-12
- AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54
- Cheetham TC, Niu F, Chiang K, et al. Factors associated with failure to achieve SVR in hepatitis C genotype 3 patients within an integrated care delivery system. J Manag Care Spec Pharm 2015;21:641-7
- BMS. Package Insert Daklinza. Princeton, NJ, USA: Bristol-Myers Squibb Company. Available at: http://packageinserts.bms.com/pi/pi_daklinza.pdf [Last accessed 15 June 2016]
- Gilead Sciences. Package Insert Epclusa. Foster City, CA, USA: Gilead Sciences, Inc. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf. Last accessed 1 February 2017
- Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45:e17-24
- McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-46
- Razavi H, El Khoury AC, Elbashs E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-70
- Gordon et al., 2013
- LaMori J, Tandon N, Laliberté F, et al. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C. J Med Econ 2016;19:364-73
- United States. The Health Insurance Portability and Accountability Act (HIPAA). Washington, D.C.: U.S. Dept. of Labor, Employee Benefits Security Administration, 2004
- Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012;56:1651-60
- United States Census Bureau. Census regions and divisions of the United States. 2015. Available at: http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf [Last accessed 12 October 2015]
- Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Am J Epidemiol. 2011 Mar 15;173(6):676-82
- United States Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999–2013, Medical Care. Washington, DC, 2014. Available at: http://data.bls.gov/cgi-bin/surveymost?su [Last accessed 12 October 2015]
- Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12 week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-35